Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT142
- Development stage
- Phase 2
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
BNT142 is an investigational mRNA-based drug developed by BioNTech for the treatment of advanced solid tumors that express Claudin 6 (CLDN6), an oncofetal antigen absent from normal adult tissues but present in various cancers including testicular, ovarian, endometrial, and non-squamous non-small cell lung cancer. The drug consists of a lipid nanoparticle-formulated RNA encoding a bispecific antibody that binds to both CD3 on T cells and CLDN6 on tumor cells. After intravenous administration, the RNA is translated in vivo into the functional bispecific antibody (RiboMab02.1), which then engages T cells to recognize and destroy CLDN6-positive cancer cells. Preclinical studies demonstrated potent antitumor activity with favorable safety profiles in animal models. BNT142 is currently being evaluated in Phase I/II clinical trials for safety and preliminary efficacy in patients with CLDN6-positive advanced solid tumors[1][2][4][5][6][7][8].
- Other names
- mRNA-encoded anti-CD3/anti-CLDN6 bispecific antibody
02
Targets
CLDN6 (Claudin-6)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on BNT142.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT142.